Autopsy report · NCT00689390

Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)

“The study was terminated due to satisfaction of post-marketing commitments”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 3 months after it had already started.
• Ran for about 7 years 8 months before it stopped.
• 1,954 participants enrolled.
• Results were posted on the registry 1 year after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2, Phase 3

Sponsor

Merck Sharp & Dohme LLC

Sponsor type

Industry

Conditions

Hepatitis C, Chronic; Hepacivirus

Interventions

Boceprevir; Narlaprevir; Peginterferon alfa-2b; Ribavirin; Blood/Plasma Collection

Participants

1,954

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.